Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKhiron Life Sciences Corp

Khiron Life Sciences Corp

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2024-04-29T17:29:13.988597Z
Market Cap
9.30M

Momentum Score

…

Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.04
Low
0.17
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
16.14M
Revenue Per Share
0.09
Gross Profit TTM
6.37M
Debt / Equity
-
ROE
-74.68%
Net Debt
-
ROCE
-57.95%
Diluted EPS TTM
-0.17

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Income before tax -33.59M -23.95M -36.36M -19.73M -4.54M
Net income -33.13M -24.04M -36.38M -19.81M -4.54M
Selling general administrative 23.99M 28.41M 35.91M 20.19M 3.31M
Gross profit 6.37M 7.01M 2.44M 0.30M -
Reconciled depreciation 1.11M 1.17M 0.94M 0.34M -
Ebit -20.03M -23.60M -35.98M -18.63M -4.52M
Ebitda -32.03M -22.44M -36.64M -19.56M -
Operating income -19.79M -23.60M -37.58M -19.90M -4.52M
Interest expense 0.45M 0.00M 0.00M 0.00M 0.00M
Tax provision -0.47M 0.09M 0.02M 0.08M -
Net interest income -0.45M - - - -
Income tax expense -0.47M 0.09M 0.02M 0.08M -
Total revenue 12.79M 8.02M 9.58M 0.89M -
Total operating expenses 32.58M 31.62M 47.16M 20.79M 4.52M
Cost of revenue 6.42M 1.01M 7.15M 0.59M -
Total other income expense net -13.36M -0.34M 1.22M 0.17M -0.02M
Net income from continuing ops -33.13M -24.04M -36.38M -19.81M -4.54M
Net income applicable to common shares -33.13M -24.04M -36.38M -19.81M -4.54M
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Total assets 42.27M 73.18M 81.91M 40.35M 2.90M
Intangible assets 0.87M 15.13M 15.55M 2.01M 0.00M
Other current assets - 14.28M 1.97M 0.08M -
Total liab 8.95M 9.95M 11.87M 14.81M 0.70M
Total stockholder equity 33.33M 63.23M 70.04M 25.54M 2.19M
Other current liab 1.89M - - 0.18M 0.21M
Common stock 146.45M 137.08M 121.29M 39.83M 4.29M
Capital stock 146.45M 137.08M 121.29M 39.83M -
Retained earnings -116.81M -83.68M -59.96M -23.59M -3.78M
Other liab 0.52M 0.90M 0.89M 5.86M -
Good will 4.08M 4.11M 4.35M 4.64M -
Other assets - - 1.34M 0.15M -
Cash 8.92M 8.17M 9.17M 14.93M 1.81M
Total current liabilities 7.72M 7.34M 8.44M 6.60M 0.70M
Short term debt - - - 0.16M -
Short long term debt 1.52M 1.08M 1.01M 0.16M -
Other stockholder equity 3.69M 9.83M 8.71M 9.30M 1.68M
Property plant equipment 13.56M 17.52M 15.86M 9.62M 0.24M
Total current assets 23.77M 36.42M 44.81M 23.93M 2.65M
Net tangible assets 28.39M 43.98M 50.14M 18.90M 2.19M
Short term investments - 0.00M 27.56M 3.95M -
Net receivables 2.88M 4.58M 4.24M 4.17M 0.29M
Long term debt 0.70M 1.71M 2.55M 2.35M -
Inventory 9.45M 8.34M 0.96M 0.24M -
Accounts payable 4.31M 6.26M 7.43M 6.44M 0.45M
Non currrent assets other - - 37.10M 16.42M -
Non current assets total 18.50M 36.76M 37.10M 16.42M -
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Investments -2.09M 27.56M -23.05M -3.95M -3.95M
Change to liabilities -2.83M -1.86M 0.85M 0.67M 0.85M
Total cashflows from investing activities -2.09M 24.87M -31.98M -9.22M -0.29M
Net borrowings -0.11M -0.56M -1.27M 11.59M 11.59M
Total cash from financing activities 10.89M 12.17M 57.00M 37.59M 5.41M
Change to operating activities -0.36M 1.39M -1.95M 0.01M -0.09M
Net income -33.13M -24.04M -36.38M -19.81M -4.54M
Change in cash -12.73M 12.30M -5.67M 13.20M 2.17M
Begin period cash flow 21.65M 9.34M 15.01M 1.81M 0.00M
End period cash flow 8.92M 21.65M 9.34M 15.01M 1.81M
Total cash from operating activities -20.40M -24.53M -30.07M -14.77M -2.91M
Issuance of capital stock 11.00M 12.94M 53.14M 0.91M -
Depreciation 1.11M 1.17M 0.94M 0.34M 0.00M
Change to inventory -1.44M -2.07M -0.70M -0.18M -0.18M
Change to account receivables 2.31M 0.61M -1.38M 0.83M -0.34M
Sale purchase of stock 0.00M -0.21M - - -
Other cashflows from financing activities - 0.58M 2.69M 2.69M 2.69M
Change to netincome 13.94M 0.28M 8.55M 3.37M 1.21M
Capital expenditures 1.74M 2.69M 6.09M 3.83M 0.29M
Change in working capital -2.33M -1.94M -3.18M 1.33M -
Stock based compensation 2.32M 5.72M 9.37M - -
Other non cash items -1.08M -5.53M -0.85M - -
Free cash flow -22.14M -27.23M -36.17M -18.60M -

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RX
Biosyent Inc.		 0.35
2.08%		 17.20 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc		 0.16
8.89%		 1.96 - 8.67 0.67 1.20 0.99 17.75
ZYUS
ZYUS Life Sciences Corporation		 0.03
9.38%		 0.35 - - 108.48 4.41 140.29 -4.26
LSL
LSL Pharma Group Inc.		 -
-%		 0.30 20.75 - 1.88 1.89 2.85 10.19

Profile*

Khiron Life Sciences Corp

Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. was incorporated in 2012 and is headquartered in Vancouver, Canada.

500 Burrard Street, Vancouver, BC, Canada, V6C 2B5

705 527 3564

https://khiron.ca

Name Title Year Born
Dr. Alvaro Francisco Torres Co-Founder, CEO & Director 1979
Ms. Franziska Katterbach Pres of Khiron Europe NA
Mr. Swapan Kakumanu ACA, ACWA, CGA Corp. Sec. 1970
Ms. Helen Bellwood A.C.A. Interim Chief Financial Officer NA
Mr. Manuel Buendia VP of Operations NA
Mr. Luis Chavez Country Mang. of Mexico NA
Mr. Marco Algorta Country Mang. of Uruguay NA
Mr. Juan Diego Alvarez VP of Regulations 1985

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.34
+14.45%
OMG
CAD 1.70
+13.76%
ARTG
CAD 39.54
+12.59%
DSV
CAD 10.83
+12.58%
TLRY
CAD 4.17
+12.10%
DRUG
CAD 25.95
-30.02%
HUT
CAD 69.16
-22.20%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.70
-15.62%
VET
CAD 15.04
-13.31%

Equity Sectors*

  • Basic Materials

    +4.80%

  • Communication Services

    +2.78%

  • Consumer Cyclical

    +2.82%

  • Consumer Defensive

    +0.74%

  • Energy

    -4.92%

  • Financial Services

    +2.47%

  • Healthcare

    -0.30%

  • Industrials

    -0.38%

  • Real Estate

    +1.75%

  • Technology

    +0.82%

  • Utilities

    +1.29%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…